BR9811780A - Método de aumento de volume ósseo usando agonistas seletivos fp não ocorrendo naturalmente - Google Patents

Método de aumento de volume ósseo usando agonistas seletivos fp não ocorrendo naturalmente

Info

Publication number
BR9811780A
BR9811780A BR9811780-7A BR9811780A BR9811780A BR 9811780 A BR9811780 A BR 9811780A BR 9811780 A BR9811780 A BR 9811780A BR 9811780 A BR9811780 A BR 9811780A
Authority
BR
Brazil
Prior art keywords
bone volume
agonists
selective
naturally occurring
volume increase
Prior art date
Application number
BR9811780-7A
Other languages
English (en)
Inventor
Richard James Hartke
Mark Walden Lundy
Mitchell Anthony Delong
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of BR9811780A publication Critical patent/BR9811780A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção: <B>"MéTODO DE AUMENTO DE VOLUME óSSEO USANDO AGONISTAS SELETIVOS FP NãO OCORRENDO NATURALMENTE"<D>. A presente invenção refere-se a novos métodos de aumento de volume ósseo compreendendo a administração de um agonistas FP seletivo não ocorrendo naturalmente a um sujeito em necessidade de tal tratamento. Esta invenção além disso refere-se a um método de tratamento ou prevenção de distúrbios ósseos compreendendo a administração de um agonistas FP seletivo não ocorrendo naturalmente a um sujeito em necessidade de tal tratamento.
BR9811780-7A 1997-09-09 1998-09-04 Método de aumento de volume ósseo usando agonistas seletivos fp não ocorrendo naturalmente BR9811780A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5830697P 1997-09-09 1997-09-09
PCT/US1998/018338 WO1999012551A1 (en) 1997-09-09 1998-09-04 Method of increasing bone volume using non-naturally-occurring fp selective agonists

Publications (1)

Publication Number Publication Date
BR9811780A true BR9811780A (pt) 2000-09-12

Family

ID=22015996

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9811780-7A BR9811780A (pt) 1997-09-09 1998-09-04 Método de aumento de volume ósseo usando agonistas seletivos fp não ocorrendo naturalmente

Country Status (20)

Country Link
US (1) US6156799A (pt)
EP (1) EP1045694A1 (pt)
JP (1) JP2001515864A (pt)
KR (1) KR20010023840A (pt)
CN (1) CN1269721A (pt)
AR (1) AR013479A1 (pt)
AU (1) AU739275B2 (pt)
BR (1) BR9811780A (pt)
CA (1) CA2303800A1 (pt)
CO (1) CO4980882A1 (pt)
HU (1) HUP0004581A2 (pt)
ID (1) ID24827A (pt)
IL (1) IL134760A0 (pt)
NO (1) NO20001171L (pt)
PE (1) PE119099A1 (pt)
PL (1) PL339288A1 (pt)
SK (1) SK3412000A3 (pt)
TR (1) TR200000662T2 (pt)
WO (1) WO1999012551A1 (pt)
ZA (1) ZA988228B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3385900A (en) * 1999-03-05 2000-09-21 Procter & Gamble Company, The Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives
EP1159266B1 (en) 1999-03-05 2004-11-03 Duke University C-16 unsaturated fp-selective prostaglandins analogs
CA2366755A1 (en) * 1999-03-05 2000-09-08 The Procter & Gamble Company Method of increasing bone volume using non-naturally-occurring ep, selective agonists
WO2000051979A1 (en) * 1999-03-05 2000-09-08 The Procter & Gamble Company C16 unsaturated fp-selective prostaglandins analogs
CA2303060A1 (en) * 1999-04-14 2000-10-14 United States Gear Corporation Towed vehicle brake controller
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US7545964B2 (en) 2000-08-29 2009-06-09 Imaging Therapeutics, Inc. Methods and devices for quantitative analysis of x-ray images
US7467892B2 (en) 2000-08-29 2008-12-23 Imaging Therapeutics, Inc. Calibration devices and methods of use thereof
US6904123B2 (en) 2000-08-29 2005-06-07 Imaging Therapeutics, Inc. Methods and devices for quantitative analysis of x-ray images
US7660453B2 (en) 2000-10-11 2010-02-09 Imaging Therapeutics, Inc. Methods and devices for analysis of x-ray images
US8639009B2 (en) 2000-10-11 2014-01-28 Imatx, Inc. Methods and devices for evaluating and treating a bone condition based on x-ray image analysis
ATE440536T1 (de) 2001-05-25 2009-09-15 Imaging Therapeutics Inc Verfahren zur diagnose, behandlung und prävention von knochenverlust
TWI313608B (en) * 2001-07-23 2009-08-21 Ono Pharmaceutical Co Lower bone mass treating agent containing er4 agonist as active ingredient
CN1893977B (zh) * 2001-07-23 2012-12-05 小野药品工业株式会社 以ep4激动剂为活性成分的治疗与骨质损失有关的疾病的药物
CA2475253A1 (en) * 2002-02-07 2003-09-04 Kathryn E. Urich Therapeutical polyanhydride compounds for drug delivery
US7840247B2 (en) 2002-09-16 2010-11-23 Imatx, Inc. Methods of predicting musculoskeletal disease
US8965075B2 (en) 2002-09-16 2015-02-24 Imatx, Inc. System and method for predicting future fractures
EP1605824A2 (en) 2003-03-25 2005-12-21 Imaging Therapeutics, Inc. Methods for the compensation of imaging technique in the processing of radiographic images
WO2005027732A2 (en) * 2003-09-19 2005-03-31 Imaging Therapeutics, Inc. Method for bone structure prognosis and simulated bone remodeling
US8290564B2 (en) 2003-09-19 2012-10-16 Imatx, Inc. Method for bone structure prognosis and simulated bone remodeling
EP1789924A2 (en) 2004-09-16 2007-05-30 Imaging Therapeutics, Inc. System and method of predicting future fractures
WO2008034101A2 (en) * 2006-09-15 2008-03-20 Imaging Therapeutics, Inc. Method and system for providing fracture/no fracture classification
US8939917B2 (en) 2009-02-13 2015-01-27 Imatx, Inc. Methods and devices for quantitative analysis of bone and cartilage

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
AU3607293A (en) * 1992-02-05 1993-09-03 Merck & Co., Inc. Implant therapy for bone growth stimulation
US5310759A (en) * 1992-08-12 1994-05-10 Bockman Richard S Methods of protecting and preserving connective and support tissues
US5409911A (en) * 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
US5747660A (en) * 1995-11-06 1998-05-05 The University Of Colorado Nucleic acid encoding prostaglandin F2α receptor regulatory protein
US5703108A (en) * 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists

Also Published As

Publication number Publication date
ZA988228B (en) 1999-03-09
CA2303800A1 (en) 1999-03-18
US6156799A (en) 2000-12-05
KR20010023840A (ko) 2001-03-26
SK3412000A3 (en) 2000-12-11
ID24827A (id) 2000-08-24
IL134760A0 (en) 2001-04-30
AU9219298A (en) 1999-03-29
AR013479A1 (es) 2000-12-27
CN1269721A (zh) 2000-10-11
PE119099A1 (es) 2000-02-03
WO1999012551A1 (en) 1999-03-18
AU739275B2 (en) 2001-10-11
TR200000662T2 (tr) 2000-07-21
NO20001171D0 (no) 2000-03-07
JP2001515864A (ja) 2001-09-25
HUP0004581A2 (hu) 2001-05-28
NO20001171L (no) 2000-05-09
CO4980882A1 (es) 2000-11-27
PL339288A1 (en) 2000-12-04
EP1045694A1 (en) 2000-10-25

Similar Documents

Publication Publication Date Title
BR9811780A (pt) Método de aumento de volume ósseo usando agonistas seletivos fp não ocorrendo naturalmente
AP2001002129A0 (en) 5HT1 receptor agonists and metoclopramide for the treatment of migrane.
BR9814923A (pt) Método para tratamento de doença de alzheimer
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
PT867178E (pt) Utilizacao de agonistas nao alostericos de gaba para o tratamento de desordens do sono
WO2000038665A3 (en) Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
BG105256A (en) Muscarinic agonists and antagonists
HK1020867A1 (en) The topical use of kappa opioid agonists to treat ocular pain k
EP1383529A4 (en) METHOD FOR THE TREATMENT OF EYES AND SQUATING TISSUES WITH THYMOSINE 4 (T 4), ANALOGUE, ISOFORMS AND OTHER DERIVATIVES
MY118986A (en) Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
HUP0101528A3 (en) The treatment of fertility disorders use of lhrh antagonists and antioestrogens in
AP1896A (en) The method of treating cancer
GB2331301C (en) Galanin
HK1112738A1 (en) Arylsulfonamides and analogues as well as use for the treatment of neuro- degenerative disorders
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
YU26401A (sh) Oralni koncentrat sertralina
CO5150204A1 (es) Metodo de aumentar el volumen oseo que comprende la administracion de un agonista fp selectivo que no ocurre naturalmente y un agonista ep1 selectivo que no ocurre naturalmente a un sujeto que requiere tal tratamiento
BR0005319A (pt) Tratamento combinado para depressão e ansiedade
WO2000051585A3 (en) Use of a non-naturally-occurring ep1 selective agonist for increasing bone volume
CO5150237A1 (es) Metodos de aumentar el volumen oseo que comprenden la administracion de un agonista fp selectivo que no ocurre naturalmente y un compuesto de antiresorcion a un sujeto que requiere tal tratamiento
AU2002358267A8 (en) Methods and compositions in treating pain and painful disorders using 1465,1587, 2146, 2207, 32838, 336 and 52908
UA20075A (uk) Спосіб діагhостуваhhя та лікуваhhя стійких фуhкціоhальhих зміщеhь hижhьої щелепи
EP1517912A4 (en) METHODS AND COMPOSITIONS FOR TREATING PAIN AND PAIN DISEASES USING GENES 577, 20739 OR 57145
EE200100122A (et) R-(+)-alfa-(2,3-dimetoksüfenüül)-1-[2-(4-fluorofenüül)etüül]-4-piperidiinmetanooli kasutamine unehäirete raviks
AUPP176098A0 (en) Methods, and compositions of treatment of chronic fatigue/pain disorders

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A,5A,6A,7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1888 DE 13/03/2007.